๐Ÿงช Beta โ€” BiohacksAI is under active development. Data and features may change.
B
BiohacksAI
Evidence-Based Biohacking
BetaPatent Pending

isorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside vs Withania

Mechanistic comparison of isorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside [Supplementary Concept] from and Withania based on molecular target overlap from BindingDB and ChEMBL binding affinity data.

3
Shared Targets
11%
Jaccard Similarity
13%
IDF-Weighted Similarity
Jaccard measures raw target overlap. IDF-weighted downweights promiscuous hub targets (e.g. CYP enzymes) that bind many compounds non-specifically.

Evidence Comparison

isorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside [Supplementary Concept] from
โ€”
Evidence Score
300
PubMed Studies
View full profile โ†’
Withania
โ€”
Evidence Score
โ€”
PubMed Studies
View full profile โ†’

Target Overlap

isorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside and Withania share 3 molecular targets based on binding affinity data from BindingDB (Kd/IC50 โ‰ค 10 ยตM) and ChEMBL. A Jaccard index of 0.107 means 11% of the combined target set is bound by both compounds. The IDF-weighted score of 0.131 accounts for non-specific binding to metabolic enzymes.

Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.

Frequently Asked Questions

What do isorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside and Withania have in common?
isorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside and Withania share 3 molecular targets with a Jaccard similarity of 11%. Both bind overlapping sets of proteins based on BindingDB and ChEMBL binding affinity data.
Can isorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside and Withania be combined?
isorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside and Withania share 3 molecular targets, suggesting potential pathway overlap. Combination use should be evaluated with a qualified healthcare professional. BiohacksAI does not provide medical advice.
Which has more research: isorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside or Withania?
Both isorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside and Withania have substantial PubMed research. View their individual profiles for full evidence scores.

Related Comparisons

Similar to isorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside

isorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside vs tamarixetin8 targetsisorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside vs withaferin9 targetsisorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside vs Hesperidin11 targetsisorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside vs Kaempferols10 targetsisorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside vs Kaempferols18 targets

Similar to Withania

Withania vs rocaglamide2 targetsWithania vs tamarixetin3 targetsWithania vs withaferin3 targetsWithania vs Rutin3 targetsWithania vs Trifluridine2 targets
View full isorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside profile โ†’View full Withania profile โ†’Browse all substances โ†’